3.3.5 VP-50406

ViroPharma is currently developing a number of RNA inhibitors for treatment of hepatitis C. The company said that laboratory studies showed that VP-50406 effectively inhibits the RNA replication of HCV. VP-50406 was in Phase II clinical trials in naive patients and non-responders. Now their website no longer mentions the product ( www.viropharma.com).